ABRX, EYET, ELN all beaten down biotech's on the rebound. ELN had a positive PR from CEO this morning concerning Tysabari and is currently up 15% today at 8.20 from comments made by CEO.
One more biotech to keep an eye on with a very large GAP to fill is CGTK..2.42. An easy doubler with any positive drug developments, patents, or partnerships.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.